BJDX - Bluejay Diagnostics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BJDX

BLUEJAY DIAGNOSTICS, INC.

NASDAQ

$0.90

▼ DOWN 1.04% (-0.01)

KEY STATISTICS

Market Cap$931.24 K

52w High$16.68

52w Low$0.83

Dividend Yield—

Frequency—

P/E-0.09

Volume11.36M

Shares Out.1.03M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Indranil Dey

COMPENSATION 2026

Salary$328,193

Stock Awards$0

Incentive Plan Pay$137,500

All Other Comp.$7,862

Total$473,555

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 10, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 13, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2026-01-29	Reverse	1:4
2024-11-18	Reverse	1:50
2024-06-20	Reverse	1:8
2023-07-24	Reverse	1:20

PRICE

$0.90 ▼ DOWN 1.04% (−$0.01)

OVERLAYS

About Bluejay Diagnostics, Inc.

https://bluejaydx.com ↗

Bluejay Diagnostics, Inc. develops the Symphony platform for blood processing and immunoassays, including point-of-care tests for allergic conjunctivitis and critical care, with ongoing development for cardiac and disease monitoring applications.

INDUSTRY

Medical - Devices

A PRODUCT BLUEJAY DIAGNOSTICS, INC. IS KNOWN FOR

Symphony System

The Symphony System is a portable biomarker detection platform that delivers rapid (20-minute), cost-effective, quantitative blood test results for conditions like sepsis, enhancing triage and treatment in acute care.